Syncom Formulations (India) Ltd - ESG Rating & Company Profile powered by AI
This dashboard contains a Q&A section for Syncom Formulations (India) Ltd. The ESG assessment for Syncom Formulations (India) Ltd indicates its transparency towards the United Nations Sustainable Development Goals. Full ESG assessment of Syncom Formulations (India) Ltd are reached by registering for free.
Syncom Formulations (India) Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.0; made up of an environmental score of 8.0, social score of 4.0 and governance score of 6.0.
6.0
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
483 | Wakamoto Pharmaceutical Co Ltd | 6.1 | High |
483 | aTyr Pharma Inc | 6.1 | High |
498 | Syncom Formulations (India) Ltd | 6.0 | High |
498 | Cann Group Ltd | 6.0 | High |
498 | Biosynex SA | 6.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Syncom Formulations (India) Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Syncom Formulations (India) Ltd disclose current and historical energy intensity?
Does Syncom Formulations (India) Ltd report the average age of the workforce?
Does Syncom Formulations (India) Ltd reference operational or capital allocation in relation to climate change?
Does Syncom Formulations (India) Ltd disclose its ethnicity pay gap?
Does Syncom Formulations (India) Ltd disclose cybersecurity risks?
Does Syncom Formulations (India) Ltd offer flexible work?
Does Syncom Formulations (India) Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Syncom Formulations (India) Ltd disclose the number of employees in R&D functions?
Does Syncom Formulations (India) Ltd conduct supply chain audits?
Does Syncom Formulations (India) Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Syncom Formulations (India) Ltd conduct 360 degree staff reviews?
Does Syncom Formulations (India) Ltd disclose the individual responsible for D&I?
Does Syncom Formulations (India) Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Syncom Formulations (India) Ltd disclose current and / or historical scope 2 emissions?
Does Syncom Formulations (India) Ltd disclose water use targets?
Does Syncom Formulations (India) Ltd have careers partnerships with academic institutions?
Did Syncom Formulations (India) Ltd have a product recall in the last two years?
Does Syncom Formulations (India) Ltd disclose incidents of discrimination?
Does Syncom Formulations (India) Ltd allow for Work Councils/Collective Agreements to be formed?
Has Syncom Formulations (India) Ltd issued a profit warning in the past 24 months?
Does Syncom Formulations (India) Ltd disclose parental leave metrics?
Does Syncom Formulations (India) Ltd disclose climate scenario or pathway analysis?
Does Syncom Formulations (India) Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Syncom Formulations (India) Ltd disclose the pay ratio of women to men?
Does Syncom Formulations (India) Ltd support suppliers with sustainability related research and development?
Does Syncom Formulations (India) Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Syncom Formulations (India) Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Syncom Formulations (India) Ltd involved in embryonic stem cell research?
Does Syncom Formulations (India) Ltd disclose GHG and Air Emissions intensity?
Does Syncom Formulations (India) Ltd disclose its waste policy?
Does Syncom Formulations (India) Ltd report according to TCFD requirements?
Does Syncom Formulations (India) Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Syncom Formulations (India) Ltd disclose energy use targets?
Does Syncom Formulations (India) Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Syncom Formulations (India) Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Syncom Formulations (India) Ltd
These potential risks are based on the size, segment and geographies of the company.
Syncom Formulations (India) Limited, a pharmaceutical company, discovers, develops, manufactures, and markets a range of healthcare products in India. The company offers approximately 300 pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoules injections, dry vial injections, dry syrups, ointments, inhalers, and herbals. Its products comprise generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also offers histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it exports active pharmaceutical ingredients and surgical products; agro and confectionary products comprising rice, wheat flour, chickpeas, soy doc, biscuits, and candies; and fasteners, steel bars, roofing sheets, and jute bags, as well as metal scrap. Additionally, the company rents properties. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.